Search the Newsreel

WAVE Life Sciences (NASDAQ:WVE) Director Adrian Rawcliffe Sells 12,700 Shares

WAVE Life Sciences (NASDAQ:WVE) Director Adrian Rawcliffe sold 12,700 shares of the company's stock for approximately $67,183. The sale occurred on August 12th when shares were trading at $5.29. Following the transaction, WVE shares fell to $5.20, near their 12-month low, and the company …

Insider Selling: WAVE Life Sciences (NASDAQ:WVE) Director Sells $42,070.00 in Stock

WAVE Life Sciences (NASDAQ:WVE) Director Heidi Wagner sold 7,000 shares of the company's stock for $42,070, reducing her position by 13.48%. The sale occurred amidst weak trading and quarterly results, with WVE shares near their 52-week low and the company reporting a loss and …

Wave Life Sciences (WVE) director’s 3,864-share tax sale under 10b5-1 plan

Ken Takanashi, a director at Wave Life Sciences (WVE), sold 3,864 shares of common stock on August 11, 2026, at a weighted-average price of $6.01 per share. This sale was made under a Rule 10b5-1 trading plan solely to cover tax obligations arising from …

Wave Life Sciences (WVE) Stock Looks Cheap After A 68% Fall But Expensive On Sales

Wave Life Sciences (WVE) stock has dropped 68.4% year-to-date, making it seem cheap, yet valuation checks still deem it expensive. The company's recent redomiciliation to Delaware aims to support access to U.S. capital markets, but its P/S ratio of 15.2x, significantly higher than the …

Wave Life Sciences Ltd. SEC Filing (Aug 12, 2026)

This article reports on an SEC Form 144 filing by Wave Life Sciences Ltd. (WVE) on August 12, 2026. The filing indicates a proposed sale of 12,700 shares of common stock by an individual, acquired through Restricted Stock Units, with an aggregate market value …

Watkins Advises Wave Life Sciences on Redomiciliation to Delaware

Latham & Watkins LLP advised Wave Life Sciences, Inc. on its redomiciliation process, changing the parent company from a Singapore entity to a Delaware corporation. This involved a scheme of arrangement under Singapore law, which received shareholder and High Court approvals and was completed …

Wave Life Sciences stock hits 52-week low at $5.01

Wave Life Sciences (WVE) stock has dropped to a 52-week low of $5.01, representing a 77% decline from its peak. Despite the significant downturn and recent disappointing Q2 2026 financial results, InvestingPro analysis suggests the stock is undervalued with a fair value of $6.36. …

RA Capital group discloses 16.8% Wave Life Sciences (WVE) ownership after redomiciliation

RA Capital Management, L.P. and affiliated entities have disclosed a 16.8% beneficial ownership stake in Wave Life Sciences (WVE) following the company's redomiciliation on August 7, 2026. This ownership, totaling 34,314,406 shares, includes common stock held directly by their fund, shares issuable from Pre-Funded …

WAVE Life Sciences (NASDAQ:WVE) Stock Price Down 6.8% - Should You Sell?

WAVE Life Sciences (NASDAQ:WVE) shares recently dropped 6.8% to $5.66 after the company reported weaker-than-expected quarterly results, including a wider loss per share and lower revenue than projected. Despite the stock trading below its moving averages and remaining unprofitable, analysts maintain a "Moderate Buy" …

Wave Life Sciences: WVE-007 and AATD programs are set for major clinical and regulatory milestones in the coming year

Wave Life Sciences' WVE-007 and AATD programs are expected to reach significant clinical and regulatory milestones within the next year. The company's strategic partnerships and strong financial standing are supporting ongoing clinical progress and a planned expansion into cardiometabolic indications. These updates were highlighted …

Wave Life Sciences Announces Completion of Redomiciliation to Delaware Corporation

Wave Life Sciences has successfully completed its redomiciliation from Singapore to a Delaware corporation, with the change taking effect after trading on August 7, 2026. All shares of the Singapore entity were exchanged for shares of the new Delaware corporation on a one-for-one basis, …

WAVE Life Sciences Ltd. (NASDAQ:WVE) Receives Consensus Rating of "Moderate Buy" from Brokerages

WAVE Life Sciences Ltd. (NASDAQ:WVE) has received a "Moderate Buy" consensus rating from 16 brokerages, with an average 12-month price target of $22.53. Despite this optimistic outlook, the company recently reported a quarterly loss and revenue that missed analyst expectations, along with a negative …

WAVE Life Sciences (NASDAQ:WVE) Shares Gap Up - Here's Why

Wave Life Sciences Completes Redomiciliation From Singapore to Delaware

Wave Life Sciences (NASDAQ: WVE) has completed its redomiciliation from Singapore to Delaware, transferring its parent company jurisdiction while retaining its Nasdaq ticker and Cambridge headquarters. This corporate restructuring, effective August 7, 2026, involved a one-for-one share exchange and is not expected to materially …

Wave Life Sciences Keeps WVE Ticker After Delaware Parent Move

Wave Life Sciences (NASDAQ: WVE) has completed its redomiciliation process, changing its parent company from a Singapore entity to a Delaware corporation. This was achieved through a scheme of arrangement where existing Singapore shares were exchanged one-for-one for newly issued common shares of the …

Analysts Just Made A Major Revision To Their Wave Life Sciences Ltd. (NASDAQ:WVE) Revenue Forecasts

Analysts have significantly downgraded their revenue forecasts for Wave Life Sciences Ltd. (NASDAQ:WVE) for 2026, now expecting a 20% decline in sales to US$52m, while losses per share are projected to remain steady at US$1.14. This revision has led to a 13% drop in …

Wave Life Sciences (WVE) files prospectus for 7.1M-share stockholder resale

Wave Life Sciences Inc. has filed a post-effective amendment to its existing shelf registration, reflecting its redomiciliation from Singapore to Delaware and adopting the prior Form S-3. The amendment covers the resale of up to 7,072,781 shares of common stock by existing selling stockholders, …

Wave Life Sciences Ltd. SEC Filing (Aug 7, 2026)

Wave Life Sciences Ltd. (WVE) filed a Form 15-12G with the SEC on August 7, 2026, certifying the termination of its registration under Section 12(g) of the Securities Exchange Act of 1934 or the suspension of its duty to file reports under Sections 13 …

Wave Life Sciences (WVE) refreshes $250M ATM and shelf after Delaware redomicile

Did U.S. Redomiciliation and Mixed 1H 2026 Results Just Shift Wave Life Sciences' (WVE) Investment Narrative?

Wave Life Sciences Announces Expected Completion Date for Redomiciliation to Delaware

Wave Life Sciences announced that its proposed redomiciliation to the United States, via a scheme of arrangement under Singaporean law, is expected to become effective after the close of trading on Friday, August 7, 2026. This follows shareholder and High Court of Singapore approvals. …

Wave Life Sciences redomiciliation to U.S. set for Friday By Investing.com

Wave Life Sciences (NASDAQ:WVE) is set to complete its redomiciliation from Singapore to the United States on Friday, August 7, 2026, after the close of trading. The biotechnology company, which develops RNA medicines for various diseases, received shareholder and Singapore High Court approval for …

Singapore High Court approves scheme for Wave Life Sciences’ Delaware move

Wave Life Sciences (NASDAQ: WVE) announced the Singapore High Court has approved its Scheme of Arrangement for redomiciliation to the United States. The move is expected to become effective after the close of trading on August 7, 2026, upon filing the court order with …

Wave Life Sciences to Present at Upcoming Investor Conferences

Wave Life Sciences announced that its management team will participate in two investor conferences in August 2026. Paul Bolno, President and CEO, will participate in analyst-led fireside chats at the BofA Securities 2026 SMID Cap Executive Insights Event and the Canaccord Genuity 46th Annual …

Wave Life Sciences (WVE) Is Down 5.2% After Wider Q2 Losses And RNA Editing Updates - What's Changed

Wave Life Sciences reported wider Q2 2026 losses of US$69.36 million and lower sales of US$2.27 million, causing its stock to drop 5.2%. Despite the financial setbacks, the company highlighted positive progress in its RNA editing and RNAi programs, particularly for its AATD therapy …

Wave Life Sciences: Obesity Drug Advances To Phase 2 With Potential For Fat Loss Without Muscle Loss

Wave Life Sciences has initiated Phase 2a of its INLIGHT clinical trial for WVE-007, an investigational obesity treatment designed to reduce body fat while preserving muscle mass. This drug aims to offer a differentiated approach compared to existing incretin-based medicines, with potential for less …

Wave Life Sciences (WVE) Stock Sinks As Losses Deepen And Revenue Dries Up

Wave Life Sciences (WVE) saw its stock drop by 4.3% following Q2 2026 earnings that revealed a widening net loss of US$69.4 million and a significant revenue decline of 73.9% year-over-year. Despite the company's reliance on its PRISM platform for RNA medicines and management's …

WAVE Life Sciences (NASDAQ:WVE) Announces Quarterly Earnings Results

Wave Life Sciences (WVE) Q2 2026 Earnings Call Transcript

Wave Life Sciences (WVE) reported Q2 2026 earnings, detailing progress in its RNAi and RNA editing pipelines, particularly for obesity (WVE-007) and liver disease (WVE-006, WVE-008). The company highlighted WVE-007's potential for fat loss without muscle degradation and announced an FDA meeting to discuss …

Earnings Flash (WVE) Wave Life Sciences Ltd. Reports Q2 Revenue $2.3M, Vs. FactSet Est of $7.4M

Wave Life Sciences Ltd. (WVE) announced its Q2 revenue of $2.3 million, falling significantly short of the FactSet estimate of $7.4 million. This earnings flash indicates a substantial miss on revenue expectations for the company.

Wave Life Flat on Q2 Figures

Wave Life Sciences Ltd. announced its financial results for the second quarter ended June 30, 2026, highlighting disciplined execution across its pipeline. CEO Paul Bolno discussed progress in its INLIGHT trial for obesity with WVE-007, aiming to demonstrate its potential for fat loss and …

WVE Looks 35.5% Overvalued on GF Value™

Wave Life Sciences Ltd (NASDAQ: WVE) is considered 35.5% overvalued according to GuruFocus' GF Value™ metric, despite its Price-to-Sales ratio being below its historical median. The company reported a significant revenue decline and continued losses in Q2 2026, though it has strong financial strength …

Wave Life Sciences (WVE) Reports Q2 Loss, Misses Revenue Estimates

Wave Life Sciences (WVE) reported a Q2 loss of $0.34 per share, missing the Zacks Consensus Estimate of a $0.31 loss. The company also posted revenues of $2.27 million, falling short of the consensus estimate by 73.48%. Despite these misses, the estimate revisions trend …